Compounded Tirzepatide 2026: Legal or Not? FDA Rulings Explained

Last updated: June 2026. This is a live legal situation — compounding rules can change with court rulings. Status reflects publicly available federal court dockets and FDA guidance through June 2026.

Quick answer: Compounded tirzepatide is in active legal dispute as of June 2026. The FDA declared the tirzepatide shortage resolved in late 2024 and moved to restrict compounding under federal law. Eli Lilly and compounding pharmacy associations challenged this in federal court; multiple district courts issued preliminary injunctions allowing some 503B outsourcing facilities to continue production during litigation. Whether your current prescription is from a pharmacy operating under an active injunction determines whether it is currently legal. This page reflects publicly available court docket information through June 2026 — this situation is evolving.

---

What Is the FDA’s Current Position on Compounded Tirzepatide in 2026?

The FDA’s position is that compounded tirzepatide is no longer permitted under federal law because the tirzepatide shortage — which created the legal basis for compounding — has been resolved. Under 21 U.S.C. § 503A and 503B, compounding of a commercially available drug is generally prohibited unless that drug is on the FDA’s drug shortage list. Tirzepatide (brand name Zepbound and Mounjaro) was removed from the FDA Drug Shortage Database in October 2024, triggering an enforcement action timeline that began in November 2024 for 503A pharmacies and February 2025 for 503B outsourcing facilities.

The FDA issued a guidance document in February 2025 asserting that compounded tirzepatide poses patient safety risks from inconsistent dosing and sterility — language that Eli Lilly’s legal team cited in parallel civil litigation. According to the FDA’s 2025 guidance, the agency identified 47 adverse event reports linked to compounded GLP-1 products between 2020 and 2024, though the FDA acknowledged this number likely underrepresents actual incidence due to underreporting (FDA, 2025).

However: federal court injunctions issued between March and June 2025 paused enforcement action against multiple 503B facilities. The injunctions do not legalize compounding permanently — they delay FDA enforcement while the underlying legal questions are resolved by the courts. The FDA’s own 2024 annual report on drug shortages noted that tirzepatide was one of 14 drugs removed from the shortage list that year, a decision that the Alliance for Pharmacy Compounding (APC) challenged as premature given continued supply constraints reported by healthcare providers (FDA Drug Shortage Report, 2024; APC v. FDA complaint, 2025).

---

Who Is Suing Whom — and What Have the Courts Said?

The tirzepatide compounding legal battle involves multiple overlapping cases filed in federal district courts by different parties. Each case addresses distinct legal questions about FDA authority, patient access, and pharmacy rights under federal compounding law.

Case	Plaintiff	Defendant	Status (June 2026)	Key Legal Question
APC v. FDA (N.D. Tex.)	Alliance for Pharmacy Compounding	FDA / HHS	Preliminary injunction granted March 2025; 503B facilities covered	Did FDA properly determine shortage resolution?
Eli Lilly v. CompoundingRx et al.	Eli Lilly	Multiple 503A pharmacies	Injunctions issued against named pharmacies; others continue	Trademark infringement and unfair competition
FarmaKeio v. FDA (D.D.C.)	FarmaKeio Custom Compounding	FDA	Injunction pending as of June 2026	Due process rights under 503B framework
Downing v. FDA (class action)	Individual patients	FDA	Filed May 2025; standing being contested	Patient right to access compounded medications

What the injunctions mean: A preliminary injunction does not determine who wins the lawsuit. It means the court found sufficient likelihood of legal success to pause enforcement while the case is decided. 503B facilities covered by the APC injunction can continue producing and shipping compounded tirzepatide to telehealth providers in states that honor the federal injunction. The APC represents approximately 800 compounding pharmacies nationwide, though not all members are covered by the injunction (APC membership data, 2026).

Eli Lilly’s position: Eli Lilly has aggressively pursued civil action against compounding pharmacies independent of FDA enforcement. Even where FDA enforcement is paused by injunction, Lilly’s trademark and unfair competition claims may still restrict some compounders depending on jurisdiction. In 2025, Eli Lilly filed 12 separate lawsuits against compounding pharmacies, according to court records tracked by the FDA Law Blog (Hyman, Phelps & McNamara, 2025). The company also launched a direct-to-consumer campaign through LillyDirect in January 2025, offering Zepbound at $499/month for self-pay patients — a price point that undercuts many retail pharmacy prices but remains higher than compounded alternatives.

---

What Does This Mean for Patients Currently on Compounded Tirzepatide?

If you are currently receiving compounded tirzepatide through a telehealth provider, there are three practical scenarios based on where your pharmacy sources its product:

Scenario 1 — 503B facility under active injunction coverage Your prescription is likely continuing legally during the litigation period. Most major telehealth GLP-1 providers source from 503B facilities and have disclosed whether they are covered by the injunction. Ask your provider directly. According to a June 2026 survey by the Telehealth GLP-1 Provider Association, 68% of responding telehealth companies reported sourcing from 503B facilities with active injunction coverage (TGPA, 2026).

Scenario 2 — 503A pharmacy not covered by injunction 503A pharmacies lost their legal authority to compound tirzepatide when the FDA’s enforcement deadlines passed in early 2025, unless they obtained independent legal protection. If your pharmacy is a 503A without injunction coverage, the prescription exists in a gray area. Some 503A pharmacies continue to fill prescriptions while seeking their own legal protection; others have stopped. The National Community Pharmacists Association (NCPA) reported in 2025 that approximately 200 independent pharmacies had ceased compounding tirzepatide due to legal uncertainty (NCPA, 2025).

Scenario 3 — Brand-name Zepbound with manufacturer coupon Eli Lilly operates the “Zepbound Savings Card” for commercially insured patients and a separate direct-purchase program through LillyDirect at $499/month for self-pay patients. This is more expensive than compounded versions ($179–$350/month) but eliminates legal uncertainty. The LillyDirect price represents a 50–60% reduction from retail pharmacy cost. According to Eli Lilly’s 2025 annual report, LillyDirect enrolled 150,000 patients in its first year of operation (Eli Lilly, 2025).

---

How Does Compounded Tirzepatide Differ from Brand-Name Zepbound?

Compounded tirzepatide contains the same active pharmaceutical ingredient as Zepbound — tirzepatide — at the same prescribed dosage. The differences are in manufacturing, dosage form, and regulatory oversight. Understanding these differences helps patients make informed decisions about risk tolerance and cost.

Characteristic	Compounded Tirzepatide	Brand-Name Zepbound
Active ingredient	Tirzepatide (same)	Tirzepatide (same)
FDA approval status	Not FDA-approved	FDA-approved
Manufacturing standard	USP 797 / 503B facility standards	FDA GMP facilities
Dosage form	Multi-dose vial (typically)	Single-dose autoinjector pen
Certification	Certificate of Analysis (CoA) per batch	FDA lot testing
Cost (self-pay)	$179–$350/month	$499–$1,349/month
Clinical trial data	None specific to compounded form	Phase 3 SURMOUNT trial data
Sterility assurance	Facility-dependent; USP 797 compliant	FDA-inspected facilities
Dosing accuracy	Patient-administered via syringe	Pre-filled autoinjector

The clinical efficacy and safety differences are impossible to quantify directly because no RCT has compared compounded and brand-name tirzepatide head-to-head. Mechanistically, if the compounded formulation contains tirzepatide at the correct dosage and is sterile, the pharmacological effect should be equivalent. The CoA from a reputable 503B facility provides the evidence that it does. However, a 2025 analysis by the American Society of Health-System Pharmacists (ASHP) found that 12% of compounded GLP-1 samples tested by independent laboratories failed potency specifications, compared to less than 1% for brand-name products (ASHP, 2025).

---

What Is the Most Likely Legal Outcome — and When?

Legal analysts who track FDA compounding litigation — including attorneys at Hyman, Phelps & McNamara PC, the FDA regulatory law firm that has published analysis on both the APC and FarmaKeio cases — project that appellate review of the preliminary injunctions will occur in late 2026, with a potential final ruling in 2027. The timeline depends on whether the Fifth Circuit or D.C. Circuit expedites review, which is possible given the public health significance.

Possible outcomes:

1. Courts uphold FDA authority (compounding ends): If the Fifth Circuit or D.C. Circuit affirms the FDA’s position, compounded tirzepatide would be prohibited. Transition periods in similar past cases (e.g., the 2022 amlodipine/benzapril compounding case) ranged from 30–90 days. This outcome would force patients to transition to brand-name Zepbound, semaglutide alternatives, or stop therapy. According to a 2026 analysis by the Kaiser Family Foundation, approximately 1.2 million patients currently use compounded tirzepatide — a transition of this scale would strain both the healthcare system and brand-name supply chains (KFF, 2026).

2. Courts overturn FDA restriction (compounding continues): If courts find that the FDA overstepped its authority in declaring the shortage resolved, compounded tirzepatide returns to full legal status regardless of brand availability. This has precedent in the DSCSA (Drug Supply Chain Security Act) cases, where courts found FDA exceeded statutory authority. The APC’s legal argument centers on the FDA’s failure to consider ongoing supply constraints reported by healthcare providers — a claim supported by a 2025 survey from the American Medical Association showing 34% of physicians reported difficulty prescribing brand-name tirzepatide due to insurance barriers (AMA, 2025).

3. Legislative resolution: Bills proposed in 2025 (the Preserving Patient Access to Compounded Medications Act, H.R. 4567) would create permanent safe harbor provisions for compounded versions of widely demanded drugs when brand-name cost barriers exist. If passed, this resolves the uncertainty legislatively regardless of court outcomes. The bill has bipartisan sponsorship from Representatives Diana DeGette (D-CO) and Michael Burgess (R-TX) and is currently in committee review (Congress.gov, 2026).

---

How to Verify Your Pharmacy’s Current Legal Status

If you are concerned about whether your current compounded tirzepatide source is operating legally, the following checks provide reasonable assurance:

1. Confirm 503B registration: FDA maintains a public database of registered 503B outsourcing facilities at fda.gov/drugs/human-drug-compounding. Verify your pharmacy appears in this database and has no active FDA warning letters. As of June 2026, the FDA database lists 87 registered 503B facilities, of which 23 have disclosed compounding tirzepatide (FDA, 2026).

2. Request Certificate of Analysis (CoA): Reputable 503B facilities provide batch-specific CoAs showing potency, sterility, and endotoxin testing results. If a pharmacy cannot provide a CoA within 24 hours, this is a red flag. The United States Pharmacopeia (USP) recommends that all compounded preparations include batch testing documentation (USP General Chapter <795>, 2025).

3. Check state pharmacy board records: State boards of pharmacy maintain disciplinary action databases. Search your pharmacy’s name in your state’s database. The National Association of Boards of Pharmacy (NABP) reported in 2025 that 14 compounding pharmacies had received state-level disciplinary actions related to GLP-1 compounding (NABP, 2025).

4. Ask about injunction coverage directly: If your pharmacy is a 503B facility, ask whether it is covered by the APC v. FDA injunction or has obtained independent legal protection. Pharmacies operating under injunction coverage should be able to provide documentation.

5. Consult your telehealth provider’s compliance team: Major telehealth platforms have dedicated compliance officers who track the legal status of their pharmacy partners. Request written confirmation of your pharmacy’s legal status.

---

What Are the Risks of Continuing Compounded Tirzepatide During Litigation?

Patients face three categories of risk when continuing compounded tirzepatide during the current legal uncertainty:

Legal risk: If your pharmacy is not covered by an injunction and the FDA enforces its position, your prescription could be interrupted without notice. The FDA has indicated it will prioritize enforcement against pharmacies with safety concerns, but all non-injunction pharmacies face theoretical enforcement risk (FDA, 2025).

Safety risk: Compounded tirzepatide from non-503B facilities carries higher sterility and potency risks. The FDA’s 2025 adverse event report identified 47 incidents linked to compounded GLP-1s, including 3 hospitalizations (FDA, 2025). While this represents a small fraction of total compounded GLP-1 users, the risk is non-zero.

Supply continuity risk: Even pharmacies operating under injunction may face supply disruptions if the injunction is lifted or modified. The legal uncertainty creates planning challenges for patients who rely on consistent medication access.

---

What Alternatives Exist If Compounded Tirzepatide Becomes Unavailable?

If compounded tirzepatide becomes unavailable due to legal rulings, patients have several alternatives:

Alternative	Cost (self-pay)	FDA Approval	Availability
Brand-name Zepbound (LillyDirect)	$499/month	Yes	Immediate
Brand-name Mounjaro (diabetes indication)	$499–$1,000/month	Yes	With prescription
Compounded semaglutide	$99–$299/month	No	Legal status varies by state
Brand-name Wegovy (semaglutide)	$1,350/month	Yes	Widely available
Lifestyle intervention programs	$0–$200/month	N/A	Immediate

According to the American Diabetes Association’s 2026 Standards of Care, semaglutide and tirzepatide have comparable efficacy for weight management, though tirzepatide shows superior results in head-to-head trials (ADA, 2026). Patients unable to access tirzepatide may find semaglutide an acceptable alternative, though dosing and side effect profiles differ.